维普期刊资源整合服务平台（V6.5）

50篇 您的检索式：作者名="VASEY PA"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients显示文摘	Gifford G Paul J Vasey PA	2004	Clin Cancer Res2004，10，13：	1
2	The acquisition of hM- LH1 methylation in plasma DNA after chemotherapy pre- dicts poor survival for ovarian cancer patients 显示文摘	Gifford G Paul J Vasey PA	2004	Clin Cancer Res2004，10，：	1
3	A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate 显示文摘	McDonald AC Vasey PA Adams L	1998	Olin Cancer Res1998，4，3：	1
4	Phase Ⅲ randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma显示文摘	Vasey PA Jayson GC Gordon A	2004	J Natl Cancer Inst2004，96，22：	1
5	SCOTROC 2A:carboplat in followed by docetaxel or docetaxel-gemcitabineas first-line che- motherapy for ovarian cancer显示文摘	Vasey PA Atkinson R Osborne R	2006	BrJ Cancer2006，94，1：	1
6	Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer显示文摘	Vasey PA	2003	J Clin Oncol2003，21，10：	1
7	Maintenance erlotinib following first-line treatment with docetaxel, carboplatin and erlotinib in patients with ovarian cancer显示文摘	Vasey PA Paul J Rustin R	2007	Proc Am Soc Clin Oncol2007，25，：	1
8	Cell cycle arrests and radiosensitivity of human tumor cell lines:dependence on wildtype p53 for radiosensitivity显示文摘	Mcllwrath AJ Vasey PA Ross GM	1994	Cancer Res1994，54，14：	1
9	Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (d11520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer显示文摘	Vasey PA Shulman LN Campos S	2002	J Clin Oncol2002，20，6：	1
10	A phase I and pharmacokinetic study of LY231514, tile multitargeted antifolate显示文摘	McDONALD AC VASEY PA ADAMS L	1998	Clin Cancer Res1998，4，3：	1
11	ESMO Minimum Clinical Recommendations for diagnosis,treatment and follow-up of epithelial ovarian carcinoma显示文摘	Vasey PA Herrstedt J Jelic S	2005	Ann Oncol2005，161，：	1
12	A phase I and Pharmacokinetic study of the combination of capeeitabine and docetaxel in patients with advanced solid turnouts显示文摘	Pronk L Vasey PA Sparreboom A	2000	Br J Cancer2000，83，：	1
13	The acquisition of hMLH1 methyla- tion in plasma DNA afler chemotherapy predicts poor suJwival for o- varian cancer patients显示文摘	Gifford G Paul J Vasey PA	2004	Clin Cancer Res2004，10，13：	1
14	Phase Ⅰ trial of intraperitoneal injection of the E 1B-55-kd-gene-deleted adenovirus ONYX-015 (dl 1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer显示文摘	Vasey PA Shulman LN Campos S	2002	J Clin Oncol2002，20，6：	1
15	Phase Ⅲ randomized trial of doetaxel-csrboplatin vemus paclitaxel- carboplatinas first-line chemotherapy for ovarian carcinoma显示文摘	Vasey PA Jayson GC Gordon A	2004	J Natl Cancer Inst2004，96，22：	1
16	Phase Ⅰ clinical and pharmacokinetic study of PK1:first member of a new class of chemotherapeutic agents-drug-polymer conjugates显示文摘	VASEY PA KAYE SB MORRISON R	1999	Clin Cancer Res1999，5，1：	1
17	The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients 显示文摘	Gifford G Paul J Vasey PA	2004	Clin Cancer Res2004，10，13：	1
18	Population pharmacokinetics in phase 1 drug development:a phase 1 study of PK1 in patients with solid tumours显示文摘	THOMSON AH VASEY PA	1999	Br J Cancer1999，81，1：	1
19	Phase Ⅲ randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma显示文摘	Vasey PA Jayson GC Cordon A	2004	J Natl Cancer Inst2004，96，22：	1
20	Phase I trialo fintraperitoneal injection of the E1B-55-kd-gene delet deaden ovirus ONYX-015 (d11520)given on days 1 through 5 every 3 weeks in patients with recurrent refractory epithelial ovarian cancer显示文摘	Vasey PA Shulman LN Campos S et a	2002	Clin Oncol2002，20，2：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示